Share on StockTwits

Gilead Sciences (NASDAQ:GILD) CFO Robin L. Washington sold 33,556 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $95.56, for a total value of $3,206,611.36. Following the sale, the chief financial officer now directly owns 49,832 shares of the company’s stock, valued at approximately $4,761,946. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

GILD has been the subject of a number of recent research reports. Analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Friday, August 15th. They now have an “outperform” rating on the stock. Separately, analysts at RBC Capital initiated coverage on shares of Gilead Sciences in a research note on Friday, August 15th. They set an “outperform” rating on the stock. Finally, analysts at FBR Capital Markets initiated coverage on shares of Gilead Sciences in a research note on Thursday, August 14th. They set an “outperform” rating and a $125.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and twenty-one have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $105.05.

Gilead Sciences (NASDAQ:GILD) remained flat at $101.282 during trading on Wednesday. The stock had a trading volume of 7,067,655 shares. Gilead Sciences has a 52-week low of $57.31 and a 52-week high of $101.65. The stock’s 50-day moving average is $90.94 and its 200-day moving average is $81.53. The company has a market cap of $153.1 billion and a price-to-earnings ratio of 22.95.

Gilead Sciences (NASDAQ:GILD) last released its earnings data on Wednesday, July 23rd. The company reported $2.36 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 136.1% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $8.00 earnings per share for the current fiscal year.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.